National Institutes of Health: Anemia trials

The registry lists 80 Anemia studies with National Institutes of Health as lead sponsor. 3 are open to participants now and 19 have results posted.

Phase 1 24Phase 2 35Phase 3 7No phase 22(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism DisordersRecruitingNCT06092346
• Collection and Distribution of Samples From Healthy Donors for In Vitro Research at the NCI-FrederickEnrolling by invitationNCT00339911
• Screening for Hematology Branch ProtocolsEnrolling by invitationNCT00001620
• Treatment of Refractory Diamond-Blackfan Anemia With EltrombopagCompletedNCT04269889Phase 1/2Results posted
• Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT02048813Phase 3Results posted
• Extended Dosing With Eltrombopag for Severe Aplastic AnemiaCompletedNCT01891994Phase 2Results posted
• Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01789255Phase 2Results posted
• Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic AnemiaCompletedNCT01193283Phase 1/2Results posted
• A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic AnemiaCompletedNCT01187017Phase 1/2Results posted
• Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA TreatmentCompletedNCT00944749Phase 2Results posted
• A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia PatientsCompletedNCT00922883Phase 2Results posted
• Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)CompletedNCT00890396Results posted
• Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and AnemiaActive, not recruitingNCT00843882Phase 3Results posted
• Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic SyndromeCompletedNCT00604201Phase 2Results posted
• MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic LeukemiaCompletedNCT00462605Phase 2Results posted
• Three Immunosuppressive Treatment Regimens for Severe Aplastic AnemiaCompletedNCT00260689Phase 2Results posted
• Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan AnemiaCompletedNCT00229619Phase 2Results posted
• Alemtuzumab to Treat Severe Aplastic AnemiaCompletedNCT00195624Phase 2Results posted
• Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid LeukemiaCompletedNCT00096122Phase 1/2Results posted
• Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic AnemiaCompletedNCT00065260Phase 2Results posted
• Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell AnemiaCompletedNCT00006400Phase 3Results posted
• A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow FailureTerminatedNCT00001962Phase 2Results posted
• Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults With Sickle Cell Disease (SCD)SuspendedNCT05457790Not applicable
• Retrospective Study of Patients With Severe Aplastic Anemia Who Relapsed After Immunosuppressive TherapyCompletedNCT04436380
• Retrospective Study of Patients With Severe Aplastic Anemia Who Developed High Risk Clonal Evolution With Chromosome 7 Abnormalities After Immunosuppressive TherapyCompletedNCT04436367
• Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) HaploinsufficiencyWithdrawnNCT03733067Phase 1/2
• A Description of Bacteria in the Mouths of Patients With Severe Aplastic AnemiaCompletedNCT01900119
• Mechanisms Accounting for Unexplained Anemia in the ElderlyCompletedNCT01572506Phase 1
• Carbon Monoxide Levels and Sickle Cell Disease SeverityCompletedNCT01547793
• Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood DisordersCompletedNCT01316796Phase 1
• The Anemia Control Program: Early InterventionCompletedNCT00998998Not applicable
• Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic AnemiaCompletedNCT00767650
• A Test of Iron Malabsorption in Patients With Iron Deficiency AnemiaCompletedNCT00399191Phase 1
• Sirolimus and Cyclosporine for Treatment-Resistant Aplastic AnemiaStatus unknownNCT00319878Phase 1/2
• Etiology of AnemiaTerminatedNCT00302939
• Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory AnemiaCompletedNCT00278330Phase 1
• Blood Cell Collection for Future Use in Individuals With Fanconi AnemiaCompletedNCT00271089Not applicable
• Heart Disease in Sickle Cell AnemiaCompletedNCT00113152
• Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic SyndromesCompletedNCT00104962Phase 1
• Idiopathic Anemia of Aging (IAA)TerminatedNCT00104169Phase 2
• SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic SyndromesCompletedNCT00098826Phase 1
• XK469R in Treating Patients With Refractory Hematologic CancerCompletedNCT00095797Phase 1
• Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00087204Phase 1
• CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic PhaseCompletedNCT00084916Phase 2
• Improving Immunosuppressive Treatment for Patients With Severe Aplastic AnemiaCompletedNCT00061360Phase 2
• Collection of Biological Samples From Patients With Hepatitis-Associated Aplastic AnemiaCompletedNCT00050115
• Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP IICompletedNCT00037388
• Induction of Stable Chimerism for Sickle Cell AnemiaCompletedNCT00029393Phase 2
• Cord Blood Transplantation for Sickle Cell Anemia and ThalassemiaCompletedNCT00029380Phase 2
• Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary HypertensionCompletedNCT00023296Phase 1
• Thalidomide in Treating Patients With Myelodysplastic SyndromeCompletedNCT00015990Phase 2
• Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid CancerCompletedNCT00012376Phase 1
• Stem Cell Mobilization Potential in Patients With Aplastic Anemia in RemissionCompletedNCT00011830Phase 1
• Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan AnemiaCompletedNCT00011505Phase 2
• Oral Manifestations of Aplastic AnemiaCompletedNCT00006300
• BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid LeukemiaCompletedNCT00006213Phase 1
• Stroke Prevention in Sickle Cell Anemia (STOP 2)CompletedNCT00006182Phase 3
• Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial TherapyCompletedNCT00005942Phase 1/2
• Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic AnemiaCompletedNCT00005935Phase 2
• Tipifarnib in Treating Patients With Myelodysplastic SyndromesCompletedNCT00005845Phase 1
• Aplastic Anemia Epidemiology: Incidence and Case-controlCompletedNCT00005682
• Anemia and Surgery: Indications For TransfusionCompletedNCT00005308
• Etiology of Blood Dyscrasias: Analysis of the International Agranulocytosis and Aplastic Anemia Study DataCompletedNCT00005307
• Drug Etiology of Aplastic Anemia and Related DyscrasiasCompletedNCT00005302
• PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic SyndromeCompletedNCT00005064Phase 1
• Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic SyndromeCompletedNCT00004918Phase 1/2
• Phase II Pilot Study of Granulocyte Colony-Stimulating Factor for Inherited Bone Marrow Failure SyndromesCompletedNCT00004787Phase 2
• Stem Cell Transplantation (SCT) for Genetic DiseasesCompletedNCT00004378Not applicable
• Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic AnemiaCompletedNCT00004323Phase 2
• Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00002798Phase 3
• Combination Therapy of Severe Aplastic AnemiaCompletedNCT00001964Phase 2
• Medical Treatment for Diamond Blackfan AnemiaCompletedNCT00001749Phase 2
• Effects of Nitric Oxide and Nitroglycerin in Patients With Sickle Cell AnemiaCompletedNCT00001716Phase 2
• Comparing Therapies for the Treatment of Severe Aplastic AnemiaCompletedNCT00001626Phase 2
• Gene Therapy for the Treatment of Fanconi's Anemia Type CCompletedNCT00001399Phase 1
• Stem Cell Factor Medication for Aplastic AnemiaCompletedNCT00001398Phase 1
• Cord Blood Stem Cell Transplantation Study (COBLT)CompletedNCT00000603Phase 2
• Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG)CompletedNCT00000602Phase 2
• Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic DisordersCompletedNCT00000597Phase 3
• Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)CompletedNCT00000586Phase 3